Vice President, Global Head Sclerosis and Neuroimmunology

At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come.

Join Roche, where every voice matters.

The Vice President, Global Head Multiple Sclerosis and Neuroimmunology Product Development Clinical Science (PDC) and Disease Area Head (DAH) serves as the senior‑most expert of Multiple Sclerosis and Neuroimmunology within PDC and has ultimate ownership and accountability of the DA’s clinical development strategy. This individual is responsible for defining, leading, and overseeing the late stage strategic vision, including the clinical development strategy of Multiple Sclerosis and Neuroimmunology, and for providing inspirational leadership to the respective PDC Clinical Science team executing that strategy.

Leveraging experience and mastery in influencing across a large, matrixed enterprise this individual provides disease area and development expertise to cross‑functional life cycle teams, is the primary point of contact for business development activities in the specified DA, drives the implementation of a comprehensive end‑to‑end clinical development strategy, guides early and late‑stage portfolio asset development and teams, and actively participates in and/or chairs relevant governance bodies.

The GDAH is a critical cross‑functional connector, working in close collaboration with the Roche Group Research and Early Development organizations, Roche Diagnostics, Pharma Partnering, Pharma Technical Operations, and Global Pharma Strategy teams.

Spearhead the assigned Disease Area in partnership with the GPS Disease Area Head (DAH). Together with the GPS DAH, establish and lead a fit‑for‑purpose DA Team with DA leaders from across the Roche Group. Together with the GPS DAH, this role is accountable for the definition and execution of the global end‑to‑end DA strategy, collaborating with Roche Group Research and Early Development organizations, Roche Diagnostics, and Global Pharma Strategy teams to provide disease area and technical expertise.

Establish DA goals that serve the overarching strategic priorities, and ensure end‑to‑end prioritization of activities and implementation excellence. Represent late‑stage development and contribute to the overall portfolio strategy with internal and external stakeholders, such as Research, Early Development, Roche Diagnostics, Medical Affairs, Commercial, Regulatory and Pharma Partnering senior leaders as well as health authorities, therapeutic area societies, patient advocacy groups, and key opinion leaders.

Lead and/or define, in collaboration with functions across the drug development value chain, and in alignment with the DA strategy, asset strategies, clinical development plans, target product profiles, and clinical development stage transition decision criteria to ensure alignment with the DA strategy and achievement of the internal criteria (i.e. the Bar) for scientific rigor, patient benefit, and value. Serve as a standing member of development and business boards, and as PD co‑chair of development boards, as assigned, to provide strategic development review and advice, go/no‑go recommendations, and guidance towards maximising drug development efficiency and acceptable phase 3 PTS (probability of technical success).

Be an active member of the therapeutic area leadership team, contributing to the definition and execution of the therapeutic area strategy with an enterprise mindset.

Responsible and accountable for global clinical development. Lead the Global Development Leaders (GDLs), Medical Directors (MD)/Monitors (MM), and Clinical Scientists (CS) in their own organization or advise MDs and/or CSs in the Early Clinical Development organizations, to ensure excellence in clinical development.…